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The DNA-Mismatch Repair Enzyme hMSH2
Modulates UV-B-Induced Cell Cycle Arrest and
Apoptosis in Melanoma Cells
Markus Seifert1, Stefan J. Scherer2, Wilfried Edelmann2, Markus Bo¨hm3, Viktor Meineke4, Markus Lo¨brich5,
Wolfgang Tilgen1 and Jo¨rg Reichrath1
The mechanisms by which the post-replicative DNA mismatch repair (MMR) enzyme MSH2 is involved in the
complex response mechanisms to UV damage are yet to be clarified. Here, we show increased levels of MSH2
mRNA in malignant melanoma, metastases of melanoma, and melanoma cell (MeWo) lines as compared with
melanocytic nevi or primary cultured benign melanocytes. UV-B treatment modulated MSH2 expression and
silencing of MSH2 gene expression using small interfering RNA technology regulated UV-B-induced cell cycle
arrest and apoptosis in human MeWo. We show that MSH2-deficient non-malignant mouse fibroblasts (MEF/)
are partially resistant against UV-B-induced apoptosis and show reduced S-Phase accumulation. In addition, we
show that an Msh2 point mutation (MEFGA) that affects MMR does not affect UV-B-induced apoptosis. In
conclusion, we demonstrate that MSH2 modulates in human melanocytes both UV-B-induced cell cycle
regulation and apoptosis, most likely via independent, uncoupled mechanisms.
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INTRODUCTION
Malignant skin tumors including malignant melanoma are
frequently characterized by an increased incidence of
mutations in microsatellite repeat sequences (Quinn et al.,
1995). Microsatellite instability is a genetic mechanism
important in the development of various human cancers that
is characterized by length changes at repetitive loci scattered
throughout the genome (Charames and Bapat, 2003). In most
patients with hereditary non-polyposis colorectal cancer,
where almost every tumor reveals a high incidence of
mutations in microsatellite repeat sequences, it has been
shown that cancer predisposition is attributable to defects in
genes, which encode homologs of the microbial DNA
mismatch repair (MMR) proteins MutS and MutL (Muller
and Fishel, 2002). The MSH2 and MSH6 genes specify MutS
homologs, whereas MLH1, PMS1, and PMS2 encode homo-
logs of MutL (Marti et al., 2002). MSH2, MLH1, MSH6, and
PMS2 have been convincingly linked to susceptibility of
hereditary non-polyposis colorectal cancer. Two additional
MMR genes, MLH3 and PMS1, have also been proposed to
play a role in Lynch syndrome predisposition, but the clinical
significance of mutations in these genes is less clear
(Peltomaki, 2005). Tumor cells that display microsatellite
instability are typically defective in mismatch correction, thus
providing a direct link between MMR enzymes and genetic
stability afforded by this DNA repair system (Muller and
Fishel, 2002). The highly conserved post-replicative DNA
MMR proteins contribute to DNA replication fidelity by
removing insertion/deletion loops that result from template
primer slippage at repetitive DNA sequences and correcting
single base mismatches that escape polymerase proofreading,
thereby preventing the accumulation of spontaneous muta-
tions and ensuring the integrity and stability of the genome
(Marti et al., 2002).
Epidemiologic and in vitro studies have shown that
sunlight exposure is an etiologic agent for the development
of skin cancer (Fears et al., 1977), including malignant
melanoma (Setlow et al., 1993). The important role of the
DNA repair system in the multi-step process of melanoma
tumorigenesis is suggested by the autosomal recessive disease
xeroderma pigmentosum, in which the development of
multiple skin malignancies including malignant melanomas
early in life is associated with deficient nucleotide excision
repair (NER) of pyrimidine dimers induced by UV irradiation
(Cleaver, 1968, 1969; Sato et al., 1993). Nucleotide excision
repair represents a highly conserved DNA repair pathway
that removes lesions from the genome induced by UV-B
exposure, such as cyclobutane pyrimidine dimers and six to
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four photoproducts. Recently, conflicting evidence for a role
of MSH2 in the transcription-coupled repair pathway of
nucleotide excision repair has been reported. It has been
shown that disruptions of the MMR genes mutS and mutL
reduce transcription-coupled nucleotide excision repair of
the lactose operon in Escherichia coli (Li and Bockrath, 1995;
Mellon et al., 1996). Human cells with mutations in
particular MMR genes were likewise found to have a
deficiency in transcription-coupled repair of UV-induced
pyrimidine dimers (Mellon et al., 1996). Furthermore,
specific binding of human MSH2/MSH6 heterodimers to
DNA incorporating thymine- or uracil-containing UV light
photoproducts confirms the significance of MMR pathways
for the repair of UV-induced DNA damage, as shown in
E. coli (Li and Bockrath, 1995). The observation that Mut
homologs bind to UV light-induced photoproducts, taken
together with the concept that MutS influence UV-induced
mutability without directly removing these UV light-induced
photoproducts, has led to the hypothesis that MMR proteins
may act as a sensor of UV-induced DNA damage, mediating
a broad variety of different response mechanisms that include
effects of cell cycle regulation and induction of apoptosis.
It has been demonstrated in mammalian cells that in addition
to its role in error correction, MMR is required for apoptosis
and G2M cell cycle arrest in response to some chemical
carcinogens (Wang et al., 1999; Caporali et al., 2004).
Additionally, increased expression of MMR proteins has been
shown to induce apoptosis in various mammalian cell types
(Zhang et al., 1999).
Functional alterations in MMR are associated with visceral
malignancies and the occurrence of sebaceous skin tumors,
keratoacanthomas, and squamous cell carcinomas in the rare
autosomal dominant Muir–Torre syndrome; underlying muta-
tions were found in the MSH2 and MLH1 gene (Zhang et al.,
1999). To date, there are few studies addressing MMR protein
levels in human skin cancer samples. Varying levels of
microsatellite instability are observed in melanoma and basal
cell carcinoma; however, this indicates that MMR function
has probably been lost, but not that loss of MMR is involved
in the etiology of the disease (Hussein et al., 2001a, b;
Korabiowska et al., 2000, 2004; Kroiss et al., 2001; Ponti
et al., 2005; Sardi et al., 2000; Staibano et al., 2001).
The aim of this study was to investigate expression and
function of the DNA MMR gene MSH2 in malignant melanoma.
We asked the following questions: (i) Do we find differences in
MSH2 expression comparing samples from benign acquired
melanocytic nevi and malignant melanomas or metastases
of malignant melanoma? (ii) Do we find a mutation in the
MSH2 gene in melanoma cells (MeWo)? (iii) Is the mRNA
expression of MSH2 in MeWo regulated by UV-B-treatment?
(iv) Do changes in MSH2-expression modulate in MeWo UV-
B-induced effects on cell cycle or apoptosis?
RESULTS
Increased levels of hMSH2 mRNA in malignant melanoma and
metastases of malignant melanoma
The relative expression level of MSH2 was quantified in 18
tissue specimens from malignant melanomas and in speci-
mens from 11 metastases of malignant melanomas using
LightCycler technology and calibrator-normalized quantifica-
tion. Standard curves showed linearity over four 10-fold
dilution steps for MSH2 and b2-microglobulin as house-
keeping-gene control. A reference value was obtained by the
mean expression values of five benign melanocytic nevi.
After duplicate assessments, the mean ratio of the matched
normal samples equaled 1.00. The results are summarized in
Table 1. In samples of malignant melanomas, the expression
of MSH2 was about average 6.876.5 (mean7SD) fold higher
and in metastases of malignant melanoma, it was about
average 7.775.2 (mean7SD) as compared with benign
melanocytic nevi (Figure 1). In the individual cases, however,
there was a wide range of the expression ratio between tumor
sample and control varying between 0.5 and 45 in samples of
malignant melanoma and 0.7–23.2 in samples of metastases
of malignant melanoma.
Increased levels of MSH2 mRNA in malignant melanoma
cell lines as compared with primary cultured benign melano-
cytes. Using quantitative ‘‘Real time’’ PCR, we detected
elevated levels of MSH2 mRNA expression in melanoma cell
lines compared with cultivated benign melanocytes (Figure 2).
MSH2 expression in melanoma cell lines is modulated by UV-B
treatment
In contrast to a cutaneous squamous carcinoma cell line that
showed considerable activation of the promoter and increase
Table 1. Kalibrator normalized relative expression
level of hMSH2 in primary malignant melanoma and
metastases of malignant melanoma compared to
benign melanocytic nevi
Malignant
melanoma
Metastasis of
malignant melanoma
1 3.0 1 10.7
2 5.2 2 1.1
3 11.1 3 1.6
4 3.9 4 0.7
5 5.9 5 2.3
6 1.4 6 10.5
7 0.5 7 11.4
8 3.4 8 5.5
9 3.6 9 23.2
10 0.7 10 6.8
11 2.0 11 11.4
12 0.5 — —
13 45.0 — —
14 23.6 — —
15 3.6 — —
16 6.8 — —
17 0.7 — —
18 2.0 — —
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of MSH2 mRNA in cells after UV-B treatment, malignant
melanoma cell lines revealed time- and dose dependently
differences in MSH2 mRNA in response to UV-B (Figure 3).
At 15–30 minutes after UV-B-treatment, MSH2 mRNA levels
were marginally but reproducibly increased in cells treated
with 10 mJ/cm2 UV-B and markedly increased in cells treated
with 50 mJ/cm2 UV-B. Compared with control (non-irradiated
MeWo), the 10 mJ/cm2 UV-B-treated cells showed a reduc-
tion of MSH2 expression after 6 hours that returned to a
normal level after 36 hours. Thirty minutes after treatment
with 50 mJ/cm2 UV-B, MeWo revealed a strong induction of
MSH2 expression that thereafter continuously decreased
within 36 hours to levels below control.
Effect of UV-B-irradiation on cell cycle progression in MeWo
lines
To evaluate the effect of UV-B on the cell cycle of MeWo
cells, DNA content was serially observed after UV-B
irradiation (10 or 50 mJ/cm2). About 60% of the cells halted
transiently in the G1 phase until 12 hours after 10 mJ/cm2 UV-B-
irradiation. Cells seemed to be partially synchronized at the
G1/S boundary by the effect of UV-irradiation, as this fraction
moved as a group from S to G2 phase thereafter. From 12 to
24 hours, a rapid decrease in the fraction of G1 cells and a
reciprocal increase of cells in the S and G2/M phases was
observed (Figure 4a), suggesting that the UV-synchronized
cell fraction had passed through S Phase during this time.
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Figure 1. Relative quantification of MSH2 mRNA expression in malignant
melanoma. MSH2 mRNA expression of malignant melanomas and
metastases of malignant melanoma in relation to normal melanocytic nevi
measured by real-time PCR and calibrator normalized relative quantification
using the RelQuant Software. The relative amount of MSH2 and b2-
microglobulin was determined for each sample and one calibrator, integrated
in each Lightcycler run. A reference value was obtained by the mean
expression values of five benign melanocytic nevi. Final results expressed as
N-fold differences in target gene expression in tumor samples relative to the
normal tissue. The expression of MSH2 was about average 6.876.5 and
7.775.2 (mean7SD) fold higher in malignant melanoma and metastases
of malignant melanoma compared with benign melanocytic nevi.
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Figure 2. Relative quantification of MSH2 mRNA expression in malignant
melanoma cell lines. MSH2 mRNA expression of malignant melanoma cell
lines (SkMel30, SkMel28, MelJuso, MeWo) and cultivated benign
melanocytes measured by real-time PCR and calibrator normalized relative
quantification. The relative amount of MSH2 and b2-microglobulin was
determined for each sample and one calibrator, integrated in each Lightcycler
run. (a) Shown are the mean values and SD from three experiments. (b) N-fold
differences in target gene expression in melanoma cell lines relative to
cultivated normal melanocytes.
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Figure 3. MSH2 expression after UV-B treatment. MSH2 mRNA expression
in melanoma cell line MeWo after UV-B treatment (10 and 50 mJ/cm2)
at different times (15 minutes to 36 hours), measured by real-time PCR
(a) as described in the legend of Figure 2 and protein level (b). Treatment of
MeWo cells with 50 mJ/cm2 UV-B lead to increased levels of MSH2 RNA after
30 minutes (P¼0.035). A moderate but not statistically significant (P40.05)
increase in MSH2 expression was found after treatment of cells with
10 mJ/cm2 UV-B.
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When cells were exposed to higher doses of UV irradiation
(50 mJ/cm2), the synchronized fraction did not increase
(Figure 4b), but an increase of cells in Sub-G1 Phase was
observed (Figure 4c).
MSH2-deficient non-malignant cells (MEF/) are partially
resistant against UV-B-induced apoptosis and show reduced
S-Phase accumulation as compared with wt and cells (MEFwt)
To evaluate the effect of UV-B on the cell cycle of MSH2-
deficient cells, DNA content was serially observed in mouse
embryonic fibroblasts (MEF)/ and wild-type (wt) cells as
described for MeWo. As shown for MeWo cells, MEF/ and
wt cells were partially synchronized at the G1/S boundary
following 10 mJ/cm2 UV-B-irradiation. The proportion of
cells in S phase increased after 12 hours from 20 to 40% in
MEF wt cells (Figure 5b). In contrast, only 30% of MEF/
cells were detected in S phase (Figure 5a). The introduction of
a point mutation into the ATPase domain of the Msh2 gene
uncouples DNA repair from apoptosis (Peters et al., 2003).
Cell cycle analysis of MEF cells from mice that carry the
G674A missense mutation showed an increase of cells in
S Phase 12 hours after UV-B treatment from 27 to 45% (Figure
5c). To investigate MSH2-deficient cells for their ability to
undergo apoptosis, we irradiated MEF/ and MEFwt with
50 J/cm2 UV-B. Apoptosis was detected 18 hours after
UV-B treatment by FACS analysis using Annexin/propidium
iodide. MEF/ displayed a modest but significant decrease
in UV-B-induced apoptosis, as compared with MEFwt
(Figure 5d).
Transfection of MSH2 siRNA into human MeWo results in a
dose-dependent inhibition of hMSH2 expression
RNA interference is a post-transcriptional mechanism by
which double-stranded RNA specifically silence expression
of a corresponding gene. Small interfering double-stranded
RNA (siRNA) of 21–23 nucleotides can induce the process of
RNA interference. As a strategy to inhibit MSH2 expression at
the mRNA level, siRNAs were designed to target nucleotides
on human MSH2 mRNA. Transfection of MSH2 siRNA into
human MeWo resulted in a dose-dependent inhibition of
MSH2 expression (up to 80%). Inhibition of MSH2 mRNA
expression was maximal at 48 hours and remained sup-
pressed for at least up to 3 days (Figure 6a). The MSH2
protein level was greatly reduced as well (up to 50% at
48 hours) (Figure 6b). These studies show that MSH2-targeted
siRNAs are effective inhibitors of MSH2 expression.
Transfection of hMSH2 siRNA (siMSH2) into human MeWo
results in modulation of UV-B-induced cell cycle arrest and
apoptosis
To determine whether MSH2 is involved in signaling UV-B-
mediated effects, we used siRNA technology to inhibit its
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Figure 4. Cell cycle analysis of melanoma cell line MeWo after UV-B treatment. Cells were fixed and stained with 10 mg/ml propidium iodide as described
in Material and methods. Cell cycle profiles were determined by using the FACScan flow cytometer (Epics XL 4 CLR flow cytometer, Beckman Coulter,
Krefeld, Germany). About 20,000 cells were analyzed. Apoptotic cells were recognized as the population with DNA content less than the 2C (sub-G1) peak.
(a) Treatment with 10 mJ/cm2 caused transient G1 arrest followed by partial synchronization at the S-Phase after 12 hours (b); higher doses of UV-B (50 mJ/cm2)
revealed no accumulation of cells in S Phase but increased the fraction of Sub-G1 cells (c). Shown are the mean values and SD from three experiments.
Cells at 0 hour are non-irradiated control cells.
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expression. Transfection with siMSH2 effectively reduced
MSH2 protein level and led to slightly reduced S-phase
synchronization of MeWo in response to 10 mJ/cm2 UV-B
treatment (Figure 7a–c). Reduced apoptosis was observed in
response to higher doses (50 mJ/cm2) (Figure 7d).
No evidence for mutation in the hMSH2 gene in MeWo
The nucleotide sequence of the complete MSH2 cDNA was
determined by the dideoxy chain-termination method using
BigDye Terminator Cycle sequencing kit. When sequence
homology of the retrieved DNA sequences was examined
employing the SequencherTM DNA sequencing program, no
mutations were found. These findings indicate that MSH2 is
functional active in MeWo cells.
An MSH2 point mutation (MEFGA) that affects MMR does not
affect UV-B-induced apoptosis
MEF from mice that carry the G674A missense mutation in
the conserved ATPase region of the MSH2 gene (MEFGA)
were treated with 50 mJ/cm2 UV-B before apoptosis was
analyzed using cell death detection kit as described in
Material and methods. Although MEFGA cells showed no
modulation of apoptosis following UV-B-treatment, apoptosis
in MEF/ cells was markedly reduced as compared with
MEFwt cells (Figure 8).
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Figure 5. Effect of UV-irradiation on cell cycle progression and apoptosis of MEF/, MEFGA, and MEFwt, measured by FACS analysis. Cells were fixed
and stained with 10mg/ml propidium iodide as described in Material and methods. Cell cycle profiles were determined by using the FACScan flow
cytometer (Epics XL 4 CLR flow cytometer, Beckman Coulter, Krefeld, Germany). About 20,000 cells were analyzed. Apoptotic cells were recognized as
the population with DNA content less than the 2C (sub-G1) peak. Treatment with 10 mJ/cm2 (a–c) UV-B caused a similar effect on S phase accumulation
as shown in MeWo. MSH2-deficient cells have a significant lower portion of cells in S-phase after 12 hours then wt and mutated cells (d), and
show an decrease in (e) UV-B-induced apoptosis, as compared with wt control.
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Figure 6. Expression analysis of the MSH2 mRNA and protein in MeWo cells
at different times after siRNA treatment. The expression was measured by
real-time PCR as described in the legend of Figure 2. (a) SiRNA II shows the
best results in reduction of mRNA. (b) Efficiency of RNA interference is
monitored in siRNA II-treated MeWo by Western blot at 24, 48, and 72 hours.
(1: MSH2 siRNA, 2: non-silencing control, 3: mock transfection control).
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Reduced induction of phosphorylated H2AX in Msh2-deficient
mouse fibroblasts treated with UV-B
We have analyzed whether expression of Msh2 modulates
phosphorylation of H2AX. To test this hypothesis, Msh2-
deficient mouse fibroblasts and corresponding wt cells were
treated with 10 or 50 mJ/cm2 UV-B. Amount of gH2AX was
quantitated 30 minutes, 2, 6, and 24 hours after UV-B
treatment. In contrast to cells treated with ionizing radiation
that characteristically show specific nuclear foci (Figure 9b),
UV-B treated cells reveal homogeneous nuclear gH2AX
immunoreactivity (Figure 9c). This homogeneous nuclear
staining can be quantitated using FACS analysis. We here
report that UV-B-induced induction of gH2AX immunoreac-
tivity is markedly increased in wt cells as compared with
Msh2-deficient mouse fibroblasts. Two hours following
treatment of cells with 10 mJ/cm2 UV-B, approximately
60% of wt cells, but only 42% of Msh2-deficient mouse
fibroblasts, were positive for gH2AX (Figure 10a).
DISCUSSION
Using real-time PCR, we demonstrate elevated RNA levels for
MSH2 in malignant melanocytic skin tumors as compared
with benign acquired melanocytic nevi, and in melanoma
cell lines as compared with cultivated normal melanocytes.
Our study shows a wide range of expression ratio between
malignant tumor samples and controls that may be due to
various factors influencing the genomic stability including
sun exposure or differences in the proliferative activity of
these samples. These data are in agreement with our previous
immunohistochemical observations, demonstrating increased
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Figure 8. Apoptosis in Msh2-deficient mouse fibroblasts after UV-B
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were treated with 50 J/cm2 UV-B and harvested after 18 hours. Note that
wt cells show more apoptosis as compared with Msh2-deficient cells. No
effect on apoptosis is found in cells that are mutated in the ATPase domain of
the Msh2 gene (MEFGA).
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immunoreactivity scores for MSH2 protein in malignant
melanoma and metastasis of malignant melanoma as
compared with benign nevi (Rass et al., 2001). Increased
expression of MSH2 RNA and/or protein has been reported in
various other malignancies (Aubry et al., 2001; Leach et al.,
2000; Hamid et al., 2002; Seifert and Reichrath, 2006;
Srivastava et al., 2004). However, the underlying mechani-
sms that cause increased levels of MSH2 in malignancies are
unknown. It has been speculated that upregulation of MSH2
may be related to the genomic instability in malignant tumors
or may be related to an increased proliferation rate. Elevated
levels for MSH2 have been shown to be associated with
increased proliferation both in malignant and benign tissues
(Hamid et al., 2002). It was shown that MSH2 protein
expression varies in the normal endometrium throughout the
menstrual cycle and is positively correlated to protein
expression of the proliferation marker proliferating cell
nuclear antigen (Hamid et al., 2002). Findings published
previously indicate that the association of MSH2 expression
with proliferation may be related to MSH2-induced cell cycle
progression or growth stimulation. It has been demonstrated
that MSH2 is induced by overexpression of the transcription
factor E2F, which plays crucial roles in cell growth control
(Iwanaga et al., 2004). Moreover, MSH2 is markedly induced
by growth stimulation in fibroblasts that were rendered
quiescent by serum starvation and then stimulated to re-enter
into the cell cycle synchronously by addition of serum
(Iwanaga et al., 2004). Furthermore, MSH2 protein expres-
sion is increased in normal peripheral blood lymphocytes
when cell proliferation is induced by mitogen stimulation
(Iwanaga et al., 2004). In summary, these studies demonstrate
an association of MSH2 expression and proliferation in a
broad variety of different non-malignant and malignant
tissues. The biological consequences of this association are
not completely understood. However, it has been shown that
increased MSH2 protein expression is required when DNA
replication is activated and followed by mitosis (Marra et al.,
1996).
To gain further insights into the function of MSH2 in
malignant melanoma, we have investigated the association of
MSH2 RNA expression with cell cycle progression and
apoptosis in MeWo following UV-B-treatment. We show that
MSH2 expression is regulated time and dose dependently
following UV-B treatment. Although treatment of MeWo cells
with 50 mJ/cm2 UV-B led to increased levels of MSH2 RNA,
only a moderate increase in MSH2 expression was found
after treatment of cells with 10 mJ/cm2 UV-B. Analysis of cell
cycle progression and apoptosis analysis indicates that the
moderate increase in MSH2 expression following relatively
low (10 mJ/cm2) doses of UV-B is associated with a
synchronization of cells in the S phase (that may be induced
by a transient G1 arrest Iwamoto et al., 1999), whereas the
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Figure 9. Induction of H2AX phosphorylation in wt mouse fibroblasts.
MEF wt cells were irradiated with (b) 5 Gy X-ray or (c) 50 mJ/cm2 UV-B light,
cultivated for 2 hours and subsequently immunostained with gH2AX
antibody. The DNA was counterstained with 40,6 diamidino-2-phenylindole
and examined under a fluorescence microscope. (a) Untreated cells show
only slight immunostaining with gH2AX antibody. (b) Treatment with ionizing
radiation shows characteristically specific nuclear foci, (c) UV-B treated cells
reveal homogeneous nuclear gH2AX immunoreactivity.
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Figure 10. Quantification of cH2AX immunoreactivity using FACS analysis after treatment with (a) 10 or (b) 50 mJ/cm2 UV-B light at different times.
Cells were harvested by trypsin-EDTA treatment and resuspended at a density of 2 106/ml. After incubation with either anti-phospho-Histone H2A.X-FITC
conjugate or the negative control mouse IgG-FITC conjugate, cells were run on FACS. About 10,000 cells were analyzed. Shown are the mean values
and SD from three experiments.
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strong increase in MSH2 expression following relatively high
(50 mJ/cm2) doses of UV-B is associated with an increased
number of apoptotic cells.
We speculated whether the UV-induced synchronization
of cells in the S phase (transient G1 arrest) is reduced in Msh2
knockout mouse fibroblasts as compared with wt cells and in
MeWo following treatment with MSH2 siRNA. In concor-
dance with this hypothesis, Msh2-deficient mouse fibroblasts
and siRNA-treated MeWo revealed 18 hours after UV-B-
treatment a reduction of cells in the S phase as compared
with wt mouse fibroblasts or MeWo transfected with non-
silencing control siRNA, respectively. Reduction of number
of cells in the S phase was less pronounced in siRNA-treated
MeWo as compared with Msh2-deficient mouse fibroblasts.
This difference is most likely due to the incomplete
suppression of MSH2 expression in siRNA-treated MeWo.
In conclusion, our findings support the hypothesis that MSH2
expression modulates UV-B-induced effects on cell cycle
progression.
The contribution of MSH2 to UV-B-induced apoptosis has
been demonstrated previously (Peters et al., 2003; van
Oosten et al., 2005). We speculated that suppression of
MSH2 expression may reduce the suspectibility of cells to
UV-induced apoptosis. In concordance with this hypothesis,
we here show that Msh2-deficient mouse fibroblasts are
relatively resistant to the induction of apoptosis following
UV-B-treatment (50 mJ/cm2), as compared with wt cells.
Additionally, MSH2 siRNA-treated MeWo revealed a reduc-
tion of apoptotic cells following UV-B-treatment, as com-
pared with MeWo transfected with non-silencing control
siRNA. Reduction of apoptotic cells was less pronounced in
siRNA-treated MeWo as compared with Msh2-deficient
mouse fibroblasts. As explained before, this difference is
most likely due to the incomplete suppression of MSH2
expression in siRNA-treated MeWo. In conclusion, our
findings strongly support the concept that MSH2 expression
modulates UV-B-induced apoptosis.
Defective mismatch repair due to mutations in the MSH2
gene has been shown to be associated with microsatellite
instability and with pathogenesis of various malignancies,
including hereditary non-polyposis colorectal cancer (Muller
and Fishel, 2002). We have now analyzed the sequence of
the MSH2 mRNA in MeWo and found no mutation. These
findings are in agreement with previous studies, where no
evidence for mutations in the MSH2 gene was found in
primary cutaneous malignant melanomas (Korabiowska
et al., 2000).
It has been demonstrated previously, that the introduction
of a point mutation into the ATPase domain of the Msh2 gene
uncouples DNA repair from apoptosis (Lin et al., 2004).
Therefore, we speculated that MEFGA cells, in contrast to
MEF/ cells, do not show resistance against UV-B-induced
apoptosis. Our findings support this concept, indicating that
introduction of a point mutation into the ATPase domain of
the Msh2 gene uncouples DNA repair from UV-B-induced
apoptosis, as it has been shown for other apoptotic stimuli
before. Although the mutant MEFGA protein is capable of
mismatch binding, it does not allow normal MMR to proceed
and therefore supports the idea that MSH2–MSH6 and also
MLH1–PMS2 complexes can bind to damaged bases at the
replication fork and could block DNA replication or other
processes such as transcription and repair, leading to cell
cycle arrest and cell death. Furthermore, our findings provide
the model of Brown et al (2003), which proposes that MSH2-
MLH1 complexes act as molecular scaffolds that physically
link downstream effectors involved in DNA damage response
pathway.
One of the earliest steps in the cellular response to DNA
damage including double-strand breaks (DSB) is the phos-
phorylation of serine 139 of H2AX, a subclass of eukaryotic
histone proteins that are part of the nucleoprotein structure
called chromatin (Fernandez-Capetillo et al., 2004). Using a
fluorescent antibody specific for the phosphorylated form of
H2AX (g-H2AX), discrete nuclear foci can be visualized at
sites of DSBs, either induced by exogenous agents such as
infrared or generated endogenously during programmed
DNA rearrangements. Initial studies had observed a close
correlation between the number of g-H2AX foci and the
number of expected DSBs after irradiation with 0.6 Gy
(Rothkamm and Lobrich, 2003). Recently, a direct correlation
was observed between the number of foci and the number of
DSBs produced by decay of 125I incorporated into cellular
DNA, suggesting that each focus may represent an individual
break and that each DSB may form a focus (Sedelnikova
et al., 2002). The relationship between DSB repair and the
disappearance of g-H2AX foci is less clear. Although the
number of foci per cell was shown to decrease with repair
time after irradiation with 0.6 Gy, this was not the case after
irradiation with 12 Gy (Rothkamm and Lobrich, 2003).
In this work, we have analyzed the effects of UV-
irradiation on g-H2AX-immunoreactivity in MSH2 deficient
versus wt cells (MEF/ vs wt). Although infrared character-
istically induced visual g-H2AX foci (Figure 9b), we observed
in contrast in response to UV-radiation the induction of a
more homogeneous lawn of fluorescence rather than
countable individual foci (Figure 9c). Interestingly, induction
of g-H2AX-immunoreactivity in response to greater doses of
UV-B was decreased in MSH2 deficient as compared with wt
cells (Figure 10a and b). We speculate that the g-H2AX-
immunoreactivity pattern induced by UV-B-radiation does
not correspond to DSB, but to other cellular responses to
DNA damage, such as apoptosis. It cannot be excluded that
differences in g-H2AX-immunoreactivity pattern induced by
UV-B-radiation may be at least in part due to the transformed
nature of the cells analyzed in this study.
MATERIALS AND METHODS
Skin specimens
Five cases of acquired melanocytic nevi (dermal nevi, compound
nevi, and junctional nevi with no histological signs of dysplasia),
18 cases of malignant melanomas (superficial spreading melanomas
and nodular melanomas), and 11 cases of metastases of malignant
melanomas (skin and lymph node metastases) were analyzed.
Freshly excised skin specimens were immediately snap frozen in
liquid nitrogen. Histological diagnosis was confirmed by a certified
pathologist.
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Our study was in agreement with our institutional approval and
in adherence to the Declaration of Helsinki Principles. In form
consent was obtained of all patients.
Cell lines
Human melanoma cell lines MeWo, SkMel28, SkMel30, and
MelJuso were cultivated in Roswell Park Memorial Institute (PAA
Laboratories GmbH, Co¨lbe, Germany) with 10% fetal bovine serum
(PAA Laboratories), using 75 cm2 culture flasks (Greiner Bio-One
GmbH, Frickenhausen, Germany) as described previously. Trans-
formed mouse embryonic fibroblasts (MEFs) were cultured with
DMEM (PAA Laboratories) plus 10% fetal bovine serum, and cells
were used for experiments not more than 10 passages from frozen
stock. Melanocytes were isolated from foreskins (kindly provided by
Clinic of Urology and Pediatric Urology, University of the Saarland,
Homburg/Saar, Germany) and were cultured in vitro for several
weeks. After enzymatic digestion, epidermis cell suspension was
cultured in Melanocyte Growth Media (Basal Medium plus Growth
Factors; PromoCell GmbH, Heidelberg, Germany). Growing melano-
cytes were routinely cultivated as monolayers at 371C and in a 5%
CO2 atmosphere.
UV-B irradiation
Media was removed from 70 to 80% confluent cell cultures, cells
were rinsed with phosphate-buffered saline and exposed to UV-B
using a waldmann W lamp (UV 409T, Waldmann Lichttechnik,
Villingen-Schwenningen, Germany) and culture media was re-
placed. The intensity of the UV-B source was determined by
Waldmann UV-meter (type 585100 Waldmann Lichttechnik).
RNA extraction
Total RNA was isolated from tumor and healthy tissue using the
guanidinium thiocyanate–phenol–chloroform extraction method of
Chomczynski and Sacchi (1987). The RNA was quantified spectro-
photometrically, and its integrity was controlled by agarose gel
electrophoresis in MOPS buffer.
Reverse transcription
Before utilization, RNA was DNaseI (Promega GmbH, Mannheim,
Germany) treated. First-strand cDNA was synthesized with Omni-
script reverse transcriptase (Qiagen, Hilden, Germany) using oligo-
d(T)15 primer. The presence of contaminating genomic DNA was
excluded via reverse transcription-minus reaction.
Real-time PCR and lightcycler settings
Two microliters of a 1:5 dilution of reverse transcription-reaction
mixture were used as template for real-time PCR containing
4 mM MgCl2. After adding 2ml mix from the SYBR Green I kit
(Roche Molecular Biochemicals, Mannheim, Germany), the
volume was adjusted to 20 ml with nuclease-free distilled water.
The samples were amplified in the Lightcycler System using
forward 50-TTCATGGCTGAAATGTTGGA-30 and reverse 50-ATGC
TAACCCAAATCCATCG-30 primers for MSH2 and forward
50-CCAGCAGAGAATGGAAAGTC-30 and reverse 50-GATGCTGCTTA
CATGTCTCG-30 primers for b2-microglobulin. To ensure specificity,
a gel electrophoresis was conducted for selected samples of each
specific product. It consistently revealed bands of the expected
length.
Calculation of normalized ratio
The relative amount of target gene (MSH2) and a reference gene
(b2-microglobulin) was determined for each sample and one calibrator,
integrated in each Lightcycler run. The relative ratio of target to
reference for each sample and for the calibrator is first calculated.
This corrects for sample to sample variations caused by differences in
the initial quality and quantity of the nucleic acid – the basic concept
of each relative quantification (Roche, technical note LC 13/2001).
The target/reference ratio of each sample is then divided by the target/
reference ratio of the calibrator using relative quantification software
(RelQuant, Roche Molecular Biochemicals, Mannheim, Germany).
This second step normalizes for different detection sensitivities of
target and reference amplicons. Thus, the normalization to a
calibrator provides a constant calibrator point between PCR runs.
Final results expressed as N-fold differences in target gene
expression in tumor samples relative to the normal tissue.
RNA interference
The siRNA duplexes were synthesized by Qiagen. The sequences
targeting MSH2 gene was siMSH2-1, 50-AACCGGTTGTTGAAAGGC
AAA-30; siMSH2-2 50-AAGCCCAGGATGCCATTGTTA-30; siMSH2-3
50-AATGGAGCACCTGTTCCATAT-30; siMSH2-4 50-AAGGCATCCA
AGGAGAATGAT-30. The non-silencing siRNA was purchased from
Qiagen and used as mock controls. MeWo cells were transfected
with siRNA duplex by using RNAifect (Qiagen) according to the
manufacturer’s protocols. Transfected cells were treated with UV-B
48 hours after transfection. Efficiency of RNA interference was
monitored by quantitative ‘‘real time’’ PCR (LightCycler, Roche) and
Western blotting as described later.
Western blot analysis
Total protein extraction: protein was isolated using a double volume
of the pellet in RIPA Buffer (extraction buffer: 50 mM Tris-HCl, pH
8.0, 150 mM NaCl, 0.5 % Sodiumdeoxycholate, 0.1% SDS, and 1%
Triton X 100), and complete EDTA free protease-inhibitor-cocktail
tablets (Roche). The proteins were then detected by Western blot
analysis using a MSH2-specific primary mouse monoclonal IgG
antibody (working dilution 1:500, Merck Eurolabs, Germany). The
samples included equal volumes of protein (100 mg) and were
separated on an SDS-PAGE gel and transferred to nitrocellulose
membranes. The membranes were blocked in Tris-buffered saline
(10 mM Tris-HCl/pH 8.0, 150 mM NaCl with 0.05 % Tween 20)
containing 5 % non-fat milk powder for 1 hour at room temperature.
The primary antibody was added to the membranes (1 hour, room
temperature). After a washing step, the secondary antibody
(1:30,000 dilution goat antimouse, Sigma Immunodiagnostics,
Germany) was added. The secondary antibody is labeled with
peroxidase. A detection reagent, horseradish peroxidase-based
reagent, was added for 5 minutes (Amersham Biosciences, Buck-
inghamshire, UK). The membranes were then washed several times
using Tris-buffered saline. The immunoblots were detected after-
wards by chemoluminescence according to the manufacturer’s
instructions (Roche). Ponceau S, a water-soluble dye used for
electrophoresis, (MERCK Biosciences, Schwalbach/Ts., Germany)
was used to stain the membranes. The blot was repeated two times.
Apoptosis
Forty-eight hours post-UV-B, adherent and suspension cells were
collected. The percentage of apoptotic cells was determined by flow
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cytometric analysis (FACS) using an Annexin-FITC apoptosis Kit
(Bender, MedSystems GmbH, Vienna, Austria) and the Cell death
detection kit (Roche) according to the manufacturer’s protocols.
Experiments were carried out in duplicates and repeated two times.
Flow cytometric cell cycle analysis
Exponentially growing MeWo and MEF cells were plated on six-well
plates with a density of about 2 105 cells and exposed to 10 and
50 mJ/cm2 UV-B. Afterwards, the cells were harvested and fixed in
ice-cold ethanol (30 minutes) and incubated (30 minutes, at 371C) in
phosphate-buffered saline containing 0.05 mg/ml RNaseA. After
washing, the cells were stained with 10 mg/ml propidium iodide. Cell
cycle profiles were determined by using the FACScan flow cytometer
(Epics XL 4 CLR flow cytometer, Beckman Coulter, Krefeld,
Germany). About 20,000 cells were analyzed. Data were acquired
using selective gating to exclude most of the doublet cells. Apoptotic
cells were recognized as the population with DNA content less than
the 2C (sub-G1) peak.
Sequence analysis of the MSH2 cDNA in MeWo
The nucleotide sequence of the complete MSH2 cDNA was
determined by the dideoxy chain-termination method using BigDye
Terminator Cycle sequencing kit (Applied Biosystems, Foster City,
CA). The sequencing run was performed in a genetic analyzer
(model 310, Applied Biosystems). Sequence homology of the
retrieved DNA sequences was examined employing the SequencherTM
DNA sequencing program (Gene Codes Corporation, Ann Arbor, MI).
Flow cytometric cH2AX analysis
MEF wt and / cell cultures were irradiated with UV-B-rays (10
and 50 mJ/cm2) or X-rays (5 Gy). gH2AX immunoreactivity was
analyzed using a specific mAb (Trevigen) and a streptavidin-biotin
immunofluorescence technique. Semiquantitative analysis of 40,6
diamidino-2-phenylindole- and gH2AX-stained cells was performed
as described by Rothkamm et al (Rothkamm and Lobrich, 2003) In
short, foci of infrared-treated cells were counted by eye during the
microscopic and imaging process using  100 magnification.
In UV-B-treated cells, gH2AX-immunofluorescence was quanti-
tated using the H2A.X phosphorylation assay kit for flow cytometry
(Upstate, Dundee, UK) according to the manufacture’s protocol and
the FACScan flow cytometer.
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